Citadel Advisors
CRVS icon

Citadel Advisors’s Corvus Pharmaceuticals CRVS Stock Holding History

Citadel Advisors’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.92M Buy
267,800
+174,000
+186% +$2.78M ﹤0.01% 4752
2025
Q4 		$722K Buy
93,800
+45,600
+95% +$360K ﹤0.01% 8139
2025
Q3 		$355K Buy
48,200
+7,400
+18% +$37.9K ﹤0.01% 9958
2025
Q2 		$163K Sell
40,800
-29,800
-42% -$108K ﹤0.01% 10874
2025
Q1 		$225K Sell
70,600
-66,500
-49% -$313K ﹤0.01% 10222
2024
Q4 		$733K Buy
137,100
+78,200
+133% +$584K ﹤0.01% 7703
2024
Q3 		$311K Buy
58,900
+50,900
+636% +$183K ﹤0.01% 9261
2024
Q2 		$14.6K Sell
8,000
-6,900
-46% -$12.9K ﹤0.01% 12874
2024
Q1 		$26.5K Buy
14,900
+6,800
+84% +$14.2K ﹤0.01% 12806
2023
Q4 		$14.3K Sell
8,100
-23,200
-74% -$33.9K ﹤0.01% 12887
2023
Q3 		$45.7K Sell
31,300
-8,100
-21% -$17.1K ﹤0.01% 11851
2023
Q2 		$90.2K Buy
+39,400
New +$81.9K ﹤0.01% 11079
2023
Q1 		– Sell
-11,100
Closed -$9.44K – 14820
2022
Q4 		$9.44K Sell
11,100
-1,200
-10% -$1.06K ﹤0.01% 13682
2022
Q3 		$10K Sell
12,300
-13,100
-52% -$12.5K ﹤0.01% 12277
2022
Q2 		$25K Sell
25,400
-28,700
-53% -$35.2K ﹤0.01% 12306
2022
Q1 		$89K Sell
54,100
-7,400
-12% -$13.5K ﹤0.01% 12389
2021
Q4 		$148K Sell
61,500
-316,000
-84% -$1.23M ﹤0.01% 12275
2021
Q3 		$1.83M Buy
377,500
+362,800
+2,468% +$1.07M ﹤0.01% 6589
2021
Q2 		$39K Sell
14,700
-10,700
-42% -$29.5K ﹤0.01% 13423
2021
Q1 		$78K Buy
+25,400
New +$91.8K ﹤0.01% 12648

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Citadel Advisors's CRVS Position: Q1 2026 in Review

Citadel Advisors increased its Corvus Pharmaceuticals (CRVS) stake by 113% in Q1 2026, buying an estimated $3.74M and bringing the position to 442,522 shares worth $6.47M. The position accounts for ﹤0.01% of the portfolio, ranked #3929.

Citadel Advisors first reported a position in CRVS in Q3 2018 and has held it in 18 quarters since. 164 funds tracked by Wall St. Rank hold CRVS as of Q1 2026.

  • Citadel Advisors held 442,522 shares of Corvus Pharmaceuticals worth $6.47M as of Q1 2026.
  • Citadel Advisors bought 234,340 Corvus Pharmaceuticals shares in Q1 2026, an estimated $3.74M.
  • Corvus Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #3929 holding.
  • Citadel Advisors first reported a position in Corvus Pharmaceuticals in Q3 2018 and has held it in 18 quarters since.
  • 164 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.